BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
CLSA maintains buy on Lupin
Acquisition to be earnings per share (EPS) accretive in the first full year. GAVIS has broadened Lupin's pipeline in complex generics.